Summa Equity competed the acquisition of Olink Proteomics.

Summa Equity completed the acquisition of Olink Proteomics, a Swedish life science company. Financial terms were not disclosed. ”We are very happy to have Summa Equity as our new owner. They have shown a deep understanding of our technology and the markets we are addressing. They will be able to support us in scaling up our operations across markets and drive benefit for customers, patients and the research community,” Jon Heimer, Olink Proteomics CEO.